Clinical trial
Catheter Related - Gram Positive Bloodstream Infections
NCT00467272 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00467272 |
|---|---|
| Title | Catheter Related - Gram Positive Bloodstream Infections |
| Official title | Phase II, Open-Label Study to Evaluate the Safety and Efficacy of Daptomycin in the Treatment of Catheter-Related Gram Positive Bloodstream Infections |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Bloodstream Infection |
| Intervention type | Drug |
| Interventions | Daptomycin |
| Enrollment | 30 |
| Start date | Mar 1, 2007 |
| Primary completion | Sep 1, 2012 |
| Completion | Sep 1, 2012 |
| First posted | Apr 30, 2007 |
| Last update posted | Feb 8, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: